IMARC Group, a leading market research company, has recently released a report titled "Allergy Immunotherapies Market Size, Share, Trends and Forecast by Treatment Type, Allergy Type, Distribution Channel, and Region, 2025-2033." The study provides a detailed analysis of the industry, including the global allergy immunotherapies market size, share, trends, and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Allergy Immunotherapies Market Highlights:
- Allergy Immunotherapies Market Size: Valued at USD 3.38 Billion in 2024.
- Allergy Immunotherapies Market Forecast: The market is expected to reach USD 7.50 Billion by 2033, growing at an impressive rate of 8.29% annually.
- Market Growth: The allergy immunotherapies market is experiencing robust growth driven by the increasing prevalence of allergic conditions and rising awareness about immunotherapy as a long-term treatment solution.
- Treatment Innovation: Advanced technologies including peptide-based immunotherapies, recombinant allergens, and biologic therapies are revolutionizing allergy management.
- Regional Leadership: Europe commands the largest market share at 48.4%, driven by strong healthcare infrastructure and favorable regulatory support.
- Treatment Adoption: Subcutaneous immunotherapy (SCIT) dominates with 69% market share, supported by proven clinical efficacy and well-established treatment protocols.
- Key Players: Industry leaders include ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Holding B.V., and DBV Technologies, which dominate the market with innovative solutions.
- Market Opportunities: Growing adoption of sublingual immunotherapy (SLIT) and expansion of online pharmacy distribution channels present significant growth opportunities.
Claim Your Free “Allergy Immunotherapies Market” Insights Sample PDF: https://www.imarcgroup.com/allergy-immunotherapies-market/requestsample
Our report includes:
- Market Dynamics
- Market Trends and Market Outlook
- Competitive Analysis
- Industry Segmentation
- Strategic Recommendations
Industry Trends and Drivers:
- Rising Global Burden of Allergic Diseases:
Allergic conditions are becoming increasingly common worldwide, creating unprecedented demand for effective long-term treatment solutions. According to the World Health Organization, asthma alone affected almost 262 million individuals globally in 2019 and caused 455,000 deaths. This growing patient population is seeking alternatives to temporary symptomatic relief, driving interest in immunotherapies that can fundamentally modify immune responses. Environmental factors like pollution, climate change, and modern lifestyle choices are contributing to this surge. People living in industrialized countries are particularly affected, with allergic rhinitis, asthma, and food allergies becoming more prevalent than ever before. This massive and growing patient base is creating sustained demand for immunotherapy treatments that promise long-term desensitization and reduced severity of allergic reactions.
- Breakthrough Treatment Technologies Transforming Patient Care:
The allergy immunotherapies landscape is being revolutionized by cutting-edge technological innovations that are making treatments safer, more effective, and more personalized. Peptide-based immunotherapies represent a significant leap forward, using small peptides that mimic parts of allergen proteins to induce tolerance without triggering dangerous full immune responses. This approach dramatically reduces the risk of severe reactions that sometimes occur with traditional whole-allergen immunotherapies. The global peptide therapeutics market reached USD 42.8 Billion in 2023 and is projected to reach USD 86.9 Billion by 2032, reflecting the growing importance of this technology across therapeutic areas. Recombinant allergens are another game-changer—these genetically engineered alternatives provide purer, more consistent treatment options that can be precisely calibrated for optimal dosing and formulation. These technological breakthroughs aren't just improving safety profiles; they're achieving higher success rates in desensitizing patients to allergens, making immunotherapy a more attractive option for both physicians and patients.
- Major Regulatory Approvals Opening New Treatment Pathways:
Recent regulatory developments are significantly expanding treatment options and accelerating market growth. In February 2024, the FDA made history by approving Xolair (omalizumab) as the first medication to help reduce allergic reactions to multiple foods after accidental exposure, providing protection for adults and children aged 1 year and older with IgE-mediated food allergies. This groundbreaking approval addresses a critical unmet need for the millions of people living with potentially life-threatening food allergies. Additionally, Palforzia, the first oral peanut immunotherapy, received extended approval in July 2024 for children aged 1-3 years, expanding its original approval for patients aged 4-17 years. These regulatory milestones validate the safety and efficacy of new immunotherapy approaches and facilitate broader market access. Improved insurance coverage is following these approvals, making these advanced therapies more accessible and affordable for larger numbers of patients who can benefit from long-term allergy management solutions.
- Massive Healthcare Infrastructure Investments Driving Market Expansion:
Significant investments in healthcare infrastructure are creating favorable conditions for immunotherapy adoption across regions. In the United States, pharmaceutical industry investment remains strong, with 25 private equity deals announced in Q3 2024 worth a total value of USD 2.3 Billion. These investments are fueling research, development, and accessibility of advanced treatment options. Dubai's healthcare industry exemplifies this expansion trend, with 4,482 private medical centers and 55,208 licensed professionals operating in 2022, expected to grow further by 3-6% in facilities and 10-15% in professionals in 2023. This infrastructure development is establishing specialized allergy treatment centers with advanced diagnostic capabilities, making immunotherapy more accessible to patients who need it. The expansion of private healthcare systems, particularly in emerging markets, is promoting high-quality medical services and encouraging adoption of sophisticated immunotherapy solutions. Strategic partnerships between pharmaceutical companies and healthcare providers are accelerating market penetration and ensuring patients have access to the latest treatment innovations.
Allergy Immunotherapies Market Report Segmentation:
Breakup by Treatment Type:
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
Subcutaneous immunotherapy (SCIT) dominates with 69% market share, remaining the preferred choice for most clinicians due to its well-established efficacy in providing long-term relief from allergic conditions, particularly allergic rhinitis and asthma.
Breakup by Allergy Type:
- Allergic Rhinitis
- Asthma
- Food Allergy
- Venom Allergy
- Others
Allergic rhinitis leads with 45.3% market share, reflecting its high global prevalence and significant impact on quality of life, driving demand for long-term treatment solutions beyond symptomatic relief.
Breakup by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Hospital pharmacies account for 42% of the market, as these facilities play a crucial role in providing specialized treatments that require professional administration and monitoring, particularly for SCIT and biologic therapies.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Europe holds the largest market share at 48.4%, driven by high prevalence of allergic conditions, well-established healthcare infrastructure, strong regulatory support, and widespread adoption of both SCIT and SLIT immunotherapies.
Who are the key players operating in the industry?
The report covers the major market players including:
- ALK-Abello A/S
- Allergy Therapeutics
- Stallergenes Greer
- HAL Allergy Holding B.V.
- DBV Technologies
- Merck KGaA
- Aimmune Therapeutics
- Circassia Pharmaceuticals
- Anergis SA
- Biomay AG
Ask Analyst For Request Customization: https://www.imarcgroup.com/request?type=reportid=1401flag=E
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1–201971–6302
